Lin Wei - 01 Feb 2023 Form 4 Insider Report for Erasca, Inc. (ERAS)

Reporting relationship: Chief Medical Officer
Issuer ticker: ERAS
Reported as of: 01 Feb 2023
Net transaction value: +$7,169
SEC form: 4
Accepted by SEC: 03 Feb 2023, 07:53:58 UTC
Prior SEC filing: 03 Feb 2022
Next SEC filing: 09 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Ebun Garner, attorney-in-fact

Key filing fact

Lin Wei filed Form 4 for Erasca, Inc. (ERAS) on 03 Feb 2023.

Key facts

This page summarizes Lin Wei's Form 4 filing for Erasca, Inc. (ERAS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2023, 07:53.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: +$7,169.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ERAS transaction

Common Stock

Other

Transaction value: $7,162
Shares: +1,748
Change %: +0.56%
Price: $4.10
Shares after: 315,812
Date: 01 Feb 2023
Ownership: Direct
Footnotes: F1

ERAS transaction

Common Stock

Other

Transaction value: $7.79
Shares: +2
Change %: +0%
Price: $3.89
Shares after: 315,812
Date: 01 Feb 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERAS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +560,000
Change %
Price: $0.000000
Shares after: 560,000
Date: 01 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 560,000
Exercise price: $4.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 1,748 shares acquired under the Erasca, Inc. Employee Stock Purchase Plan (the ESPP) on June 15, 2022 and 2 shares acquired under the ESPP on December 15, 2022.

Footnote F2

1/48th of the shares subject to the option vest monthly following February 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.